>Under new mgt, the revenue haul will not shrink in the early years, but the science that it buys will deteriorate markedly.<
Do you know this? think it? or is it a personal religion like your belief in Joe Podolski?
>As a society, we'll have much less to show in R&D output for the excess spending on Avastin. OK?<
Since you asked so nicely... No, not OK. I think your premise is wrong and I don't think you understand how society can benefit if Pharamceutical companies actually begin targeting these so called "targeted" therapies.
You seem to have swallowed hook-line-and-sinker the simplistic media fluff that suggests Genentech is dead as an R&D engine because the long-time majority owner gets rid of the minority shareholders.
>Your repeatedly shrill tone invites a response in kind at last.<
You have reminded me why I had you on ignore for over a year. People who disagree with you become targets. Bye
Market Data 
Markets 
AI
